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Abstract
Multidrug-resistant organisms (MDRO) pose a great threat to health across the globe. That
threat is also felt in the Veterans Health Administration (VHA). Wounded warriors returning
home from the battlefields of Iraq and Afghanistan may have brought with them MDROs, such
as the bacterium Acinetobacter baumannii, as they have transitioned from military service into
the VHA facilities. This study investigates the interconnectedness of military service in the
Department of Defense (DoD) and a lifetime of care at VHA through a longitudinal tracking of a
linked cohort of combat veterans with battlefield injuries and subsequent MDR infections of A.
baumannii. This study has sought to understand the spread of this MDRO beyond returned
combat veterans as a potential reservoir to others throughout the nationwide VA healthcare
system. This study will highlight the downstream implications of emerging MDROs brought
back home from future foreign wars and campaigns that U.S. Armed Forces become engaged in.
Furthermore, it will underscore the need for modernization of the current MDRO identification
and surveillance capabilities of VHA to adopt more utility of available molecular techniques.
With appropriate pathogen identification and surveillance, this knowledge can have a significant
impact on infection prevention and control programs, antibiotic stewardship plans and drug
formularies that are used both locally and nationwide.
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Chapter 1 – Introduction
Research Question
Multidrug-resistant organisms (MDRO) have long been recognized as a tremendous global threat
as they show more and more resistance to commonly used antibiotics used to treat common
infections [3]. Many experts have warned of what is referred to as the post-antibiotic era, in
which the drugs that we have relied upon for decades will become less reliable and even
completely ineffective at treating and managing bacterial infections due to drug resistance.
The Veterans Health Administration (VHA), the healthcare arm of the Department of Veterans
Affairs (VA), is the largest integrated healthcare system in the United States of America serving
9 million military veterans in all 50 states and territories. VHA hospitals and clinics lie
downstream from those in the Department of Defense (DoD) as military personnel transition
from military service to civilian service in VA. This study examined the relationship of incidence
of carbapenem-resistant Acinetobacter baumannii (CRAb) infections, an MDRO, from the
increase in enrollments of military veterans with a combat deployment to either Iraq or
Afghanistan in support of Operation Iraqi Freedom (OIF) or Operation Enduring Freedom (OEF),
respectively.

Specific Aims
This study has sought to demonstrate the interconnected nature of the relationship between
DoD and VHA by showing increased incidence rate in the number of CRAb infections across VHA
associated with returning wounded warriors from the battlefields of Iraq and Afghanistan as a
possible reservoir and their subsequent enrollment in VHA. While this DoD-VA connection of
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disease exposure has been inferred in an upstream to downstream relationship, it has not ever
been demonstrated across the entire VA healthcare system using VA data[4, 5].
The DoD has invested a great deal of resources into the molecular identification and
surveillance of MDROs within its population across the organization. This information is
available to military physicians and other professionals through electronic databases and other
partnerships [4-7]. However, across its 153 medical centers and hospitals, VHA does not
currently utilize advanced molecular methods of identification or surveillance for MDROs or
underutilizes existing molecular techniques such as polymerase chain reaction (PCR) [8]. This
makes it challenging for physicians to know exactly which pathogen they are initially faced with
as they treat their patients. Modernization of laboratory pathogen identification practices
using molecular techniques such as quantitative polymerase chain reaction (qPCR), pulsed field
gel electrophoresis (PFGE), ribotyping and whole genome sequencing (WGS) would allow for
adequate identification and molecular surveillance of MDROs to be conducted across the entire
across the organization [9].

Significance
The findings of this study demonstrate the interconnectedness of the DoD and VA and the
downstream implications for infectious diseases with such a relationship. These implications
will have impacts on drug formularies used in treatment of infections, antibiotic stewardship
plans, and infection control policies at both the local and national level. Furthermore, this
study has underscored the importance of adopting molecular microbial identification and
surveillance practices that will prevent the spread of MDROs for existing veteran patients and
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improve the transition of wounded warriors to VA health care and their treatment outcomes
while at VHA.

Chapter 2 – Background
Description of the Health Problem
The two major conflicts that the Unites States has most recently been engaged in are Operation
Enduring Freedom (Greater
Southwestern Asia, the Philippines,
and North Africa) and Operation
Iraqi Freedom (Greater Middle
East) as seen in Figure 1. Many
military personnel would serve
multiple combat tours in one or
both theaters of operation. The
nature of combat in these two
conflicts have been conventional as
has been the case in many previous

Figure 1. Map of Operation Enduring Freedom and Operation
Iraqi Freedom as of December 2008. Source: [2]

wars, but one distinctive characteristic about these two wars are the enemy’s use of improvised
explosive devices (IEDs) or roadside bombs detonated remotely when U.S. forces are in
proximity to the device. These explosive devices have caused a great deal of casualties across
the two battlefields. Casualty rates show an increase in the comparison of wounded casualties
to fatalities compared to previous U.S. conflicts in Vietnam and the Persian Gulf. Mortality rates
7

are relatively low considering the length of both campaigns and the technicalities of combat
across these two theaters [10]. However, combat lifesaving first aid and advances in battlefield
medicine and body armor have resulted in many wounded warriors returning from these
battlefields with a variety of injuries resulting in increased survivability [7, 11].
Battlefield triage takes place within combat zones, especially regarding trauma cases resulting
from combat injuries. These levels are defined in Table 1. Many wounded warriors requiring
medical evacuation (MEDEVAC) have sustained significant bone and soft tissue damage and due
to the nature of combat injuries, widespread wound contamination, which make up care levels
IV and V. This made infection control along MEDEVAC pathways difficult to manage [4, 5].
Table 1. Trauma Care Levels Within Combat Zones
Level

Definition

I

Point of injury/first responder care

II

Resuscitation and surgical stabilization at medical units

III

Medical/surgical care at combat support or other theater hospitals

IV

Evacuation to regional medical center location (Landstuhl Regional Medical Center, Germany)

V

Definitive treatment/rehabilitation at major tertiary care medical centers in United States

34% of combat casualties that were medically evacuated from the combat zone were diagnosed
with an infection during their hospital stay. 20% involved skin and soft tissue infection (SSTI)
and another 6% were osteomyelitis [12]. Epidemiology studies of war infections suggest that
the majority of those evacuated under Level IV and V trauma are due to Gram negative bacteria
species, including A. baumannii [13, 14]. However, while A. baumannii has represented a
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significant burden of the battlefield infection complications among wounded casualties, A.
baumannii is not captured in ICD-9 codes within the JTTR and therefore underrepresented in
clinical significance studies [11]. Complications from battlefield injuries, such as combat-related
infections, can persist long after departure from military service and into civilian life where this
study focuses [5].

Scientific Background
Acinetobacter baumannii is a gram-negative coccobacillus bacterial organism with a well-known
reputation as an opportunistic nosocomial pathogen due to its environmental resilience by
avoidance to desiccation on fomites, contaminating hospital environments, and its multidrugresistant profile [7, 14-20]. Although not a particularly virulent wild type organism (in its
natural state), when put under constant stress conditions, such as antimicrobial pressure, it can
manifest its ability to be very problematic for hospitals for this is how this organism can shift in
its expressed phenotype from being sensitive to antimicrobial drugs to a resistance of
antimicrobial drugs [16, 21]. Not only is this organism a threat to patients, but staff alike. One
such documented case demonstrated an occupational transmission of this organism from an
infected patient to healthcare worker [22]. A. baumannii is known to possess a rather large
resistome, which is the collection of genes that enable antibiotic resistance and that give this
organism its competitive edge against treatment drugs [23]. This bacterium is unique in that it
has acquired an ability to demonstrate resistance to
carbapenem antibiotics, a class of beta-lactam
antibiotics active against many Gram-positive and

Figure 2 – Mechanism of activity among
carbapenemase enzymes on carbapenem
antibiotics
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Gram-negative organisms; these drugs are usually reserved for the most resistant infections
which this study has focused on [3, 24]. A. baumannii also belongs to another class of
concerning pathogens, namely the ESKAPE pathogens. The ESKAPE pathogens are a group of
bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter Sp.) that present difficult-to-treat
options for physicians due to acquired resistance genes, the increase in disease burden and
increased mortality rates due to treatment complications and demand a coordinated global
response for surveillance of antimicrobial resistance[21].
Carbapenem-resistant Acinetobacter baumannii (CRAb) include a highly problematic class of
MDROs, namely the carbapenemase-producing organisms (CPO). There are many mechanisms
resulting in the CRAb phenotype: namely efflux pumps, pathogenic gene islands within its
genome, which promote horizontal gene transfer through the use of plasmids and include
carbapenem-hydrolyzing oxacillinase-encoding genes
(Oxa23-like, Oxa24-like, Oxa51-like, Oxa58-like), other
beta-lactamase enzymes, the ability to make
adjustments to outer membrane proteins such as
penicillin binding proteins, or make adjustments to
metabolic pathways (porins) and the ability to produce

Figure 3 – Electron Micrograph of a biofilm
Acinetobacter baumannii on collagen
substrate

biofilms [16, 21, 25-28]. Plasmids are of particular

Source: Bone and Joint Research Lab, University of Utah[1]

concern for spreading antimicrobial resistance because
contained within plasmids are integrons. A. baumannii contains both class I and class II
integrons which have been strongly associated with antibiotic resistance and the spread of
10

resistance in healthcare settings from contact with other bacteria in the hospital environment
such as Enterobacteriaceae or Pseudomonas species. The most notable example of integron
transfer between species of bacteria is that of Pseudomonas and A. baumannii with the
attainment of the class I integron which contains blaVEB-1 extended-spectrum β-lactamase
(ESBL) and six other antimicrobial resistance genes, obtained from P. aeruginosa [14, 20].
One study, examining carbapenem-resistant Gram-negative organisms, discovered that among
CPOs, the carbapenem resistance rate in A. baumannii was 40.1% in blood samples, 50.4% in
respiratory samples, 42% in urine samples, and 42% in other types of samples [29]. Morbidity is
also impacted as those patients with carbapenem-resistant (CR) infections had much longer
length-of-stay in both general medical and intensive care wards. The crude odds ratio for
hospitalization mortality comparing (CR) vs. carbapenem-sensitive (CS) organisms were 1.31 for
Escherichia coli isolated from respiratory samples to 3.91 for A. baumannii isolated from blood
samples. Overall, patients with CR infections had longer hospital stays, more antibiotic drug
treatment, higher mortality rates and higher economic burden to the hospital than those with
CS infections [29].
In 2019, the Centers for Disease Control and
Prevention (CDC) has reclassified CRAb from
a serious threat in its last report in 2013, to
an urgent threat, the most perilous
classification in its threat assessment matrix.

Figure 4 – CDC assessment of CRAb and its impact to
morbidity, mortality, and economic burden.
Source: Centers for Disease Control and Prevention[3]

CRAb has been responsible for approximately
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8,500 hospitalizations, 700 deaths and healthcare costs totaling $281M in the United States
alone in 2017[3].
Risk factors for MDRO infections include chronic obstructive pulmonary disease (COPD),
diabetes mellitus, renal disease, excessive alcohol consumption, smoking and other
immunocompromising conditions such as cancer and organ transplants [24]. This is of
particular concern for the population of VHA, where its members are disproportionately older
in age and exhibit more comorbidities than the general population [30]. For example,
prevalence of diabetes mellitus in the VHA population is 25%, while the general population is
approximately 13% [30, 31]. Furthermore, due to the occupational hazards and unique
exposures of military service, such as burn pits or radiation exposure, healthcare delivery
among the veteran population is very unique [32]. High prevalence of risk factors such as these
in VHA makes management and treatment of bacterial infections challenging, let alone the
treatment of MDROs [26].
While infection cases of A. baumannii in the United States are not uncommon, multidrugresistant strains of A. baumannii infection cases in the United States, once rare, are on the rise
[3, 15]. CRAb was not observed in the VA on a large scale until wounded warriors began
integrating into VA hospitals and clinics from the OEF/OIF battlefields they were casualties on
while in military service [33].
The DoD has invested a great deal of resources into molecular technologies (such as whole
genome sequencing) in the identification and surveillance of CRAb and other MDROs, which
have originated from Operation Enduring Freedom (Afghanistan)/Operation Iraqi Freedom
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(Iraq) (OEF/OIF) battlefields [4, 5, 7, 14, 34]. DoD healthcare and research laboratories have
been able to identify and track patient samples using these molecular techniques [6].
Unfortunately, the VA does not have this level of molecular granularity in its in-house
laboratory practices for routine surveillance purposes and therefore the identification of clonal
outbreaks of CRAb and other MDROs can be challenging [6, 8].
Furthermore, because CRAb from OEF/OIF battlefields has a much different antibiotic
resistance profile from other A. baumannii strains encountered in the United States, the
implications on the effectiveness of the current drug formulary used by VA physicians and
pharmacies are significant [6, 35]. With advanced knowledge, using proposed laboratory
pathogen identification practices as an outcome recommendation of this study, improvements
to the facility level or national level Antibiotic Stewardship plan could be applied and
appropriate drugs or combination of drugs to produce favorable treatment outcomes will be
possible [9]. But currently, VA physicians and pharmacists do not have comprehensive
information to design the appropriate treatment plan that will produce the most favorable
outcomes as possible and mitigate the spread of MDROs.

Limitations and gaps in existing literature
Previous studies [4, 5] assessing the long-term impact of battlefield injuries have only
considered complications from battlefield trauma but have not considered the impact of a
foreign MDROs such as CRAb to an entire hospital system with a vulnerable population. This
study has assessed the risk this exposure will have on not just one medical center, but across
the entire organization.
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Chapter 3 – Data and Methods
Study design
This study was designed as a retrospective case control study relating the migration of CRAb
from DoD battlefields to VHA facilities. It was hypothesized that the prevalence of CRAb in VHA
has been relatively low prior to the recent conflicts in Iraq and Afghanistan. It was further
hypothesized that due to the influx of enrolled combat veterans in VHA, particularly after the
troop surge of 2007, that incidence rates of CRAb cases would increase significantly across the
organization. Comparing the number of CRAb cases to the number of enrolled OEF/OIF
veterans that have entered VHA should show significant correlation. Counts of carbapenem
resistant Acinetobacter baumannii (CRAb) infections among hospitalized patients was tracked
each year for purposes of incidence monitoring in the VA population nationwide. Inclusion of
A. baumannii that did not fit the operational definition for CRAb was included as well for
comparison purposes as screening/identification for MDROs such as CRAb was not consistent
across VHA [8]. As a result, there may be some cases of CRAb that are underrepresented in
VHA.

Data Sources and Measurement
The VHA has been a pioneer in the electronic health record, with structured medical data
available nationwide as early as 1999. VHA stores patient-level data in a hierarchical health
information system called Veterans Health Information Systems and Technology Architecture
(VistA). This information is made available to authorized data users through access to the VA
Corporate Data Warehouse (CDW) and VA Informatics and Computing Infrastructure (VINCI),
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which is a high-performance computing environment that provides research teams with a
secure and central location for data access and application development. The CDW is used
throughout the entire healthcare system and therefore can be used to survey patient records
using Microsoft Structured Query Language (SQL) programming in a relational database
environment. Adding to these capabilities is a data source known as DoD and VA Infrastructure
for Clinical Intelligence (DAVINCI), which uses the Observational Medical Outcomes Partnership
(OMOP) and Common Data Model (CDM). Using a common patient identifier and primary key
across both data sources will allow for identification of those patients who sustained battlefield
injuries while in active-military status and allow for further observation of this cohort as they
move within the VA system.
Data collection for this project was completed under a study protocol approved by the
University of Utah School of Medicine, Department of Internal Medicine Institutional Review
Board (IRB) for use in the Veterans Health Administration. Data extraction for this project was
performed in Microsoft SQL Server Management Studio 18 (Microsoft Redmond, WA).

Setting and study population
During the early stages of the OEF/OIF conflicts, the incidence of Acinetobacter spp. was noted
among casualties and among environmental samples of MTFs across the two battlefield
theaters [7]. This study examined a sample of cases from the DoD in which battlefield injuries
were or were not sustained on OEF/OIF battlefields from 2008-2012* resulting subsequent
infections from A. baumannii and CRAb. Battlefield injury status was indicated by a flag within
the DAVINCI database. This group of OEF/OIF combat soldiers would be followed into VHA to
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see if incidence of CRAb would increase across the organization. Another sample of controls
consisted of OEF/OIF era Veterans that did not deploy to OEF/OIF battlefields.
*Note: There is a limitation of the DAVINCI data source in that battle injury and clinical
microbiology laboratory data are only available from 2008 forward. As a result, analysis of data
from earlier in the two conflicts (2003-2007) were not available.
Within VHA, nationwide cohort of combat veterans was retrospectively created from the period
2003 through 2010 who served in either OEF or OIF. Another retrospective cohort of patients
was created along the same period, who did not have a deployment to Iraq or Afghanistan.
These combat deployments were identified by a flag and record of presence or absence of
combat dates within the CDW. All patients were hospitalized with microbiology cultures
identifying A. baumannii or CRAb.
A somewhat related, but more in-depth longitudinal study conducted by Tribble et al. [21,22]
examined a cohort of battlefield injuries in what is known as the Trauma Infectious Disease
Outcomes Study (TIDOS). The TIDOS cohort was studied to evaluate both short and long-term
infectious complications for those who sustained deployment-related injuries from Operation
Enduring Freedom and Operation Iraqi Freedom combat theaters. Utilizing this same cohort is
not feasible for the scope of this project, as the cohort was limited to only one VA medical
center. For the purposes of this study, a nationwide cohort of enrolled Veterans Affairs
patients who experienced battlefield trauma/injury was assessed.
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Variables
Table 2. Variables of Consideration
Outcome
DoD CRAb
DoD Ab
VHA CRAb
VHA Ab
OEFOIF CRAb
OEFOIF Ab

Exposure
Sustained battlefield injury
Sustained battlefield injury
OEF/OIF Era Veteran
OEF/OIF Era Veteran
OEF/OIF Combat Deployment
OEF/OIF Combat Deployment

Operational Definitions
VHA defines a multi-drug resistant organism (MDRO) as: “microbes able to withstand the killing
or inhibitory effect of several different antimicrobial agents. The exact number and types of
antimicrobial classes to which a microorganism is resistant varies depending on the pathogen
“[36].

Table 3. Detailed Pathogen Phenotype Definition
Pathogen

Organism

Numerator

Denominator

Carbapenem-

Acinetobacter

Imipenem,

Any isolate with at least

Any isolate with

resistant

baumannii

meropenem,

1 non-susceptible result

at least 1

doripenem

(I or R) to: imipenem,

susceptible (S) or

meropenem, doripenem

non-susceptible

Acinetobacter sp.

Medications

result (I, R) to at
least 1 drug in the
medications
category
Acinetobacter sp.

Acinetobacter

Imipenem,

Any isolate with at least

Any isolate with

baumannii

meropenem,

1 susceptible result (I or

at least 1
17

Calcoaceticus
complex

doripenem

R) to imipenem,

susceptible result

meropenem, doripenem

(I, R) to at least 1
drug in the
medications
category

Analytic Plan
Incidence rates of CRAb were calculated amongst the combat Veteran cohort as well as those
who do not have a history of recent combat (with and without exposure).
Incidence rate ratios were calculated among DoD personnel with battlefield injuries, among
VHA OEF/OIF era Veteran patients and among OEF/OIF era Veteran patients with a combat
deployment to OEF or OIF battlefields to assess the risks of these exposures. Subsequent trend
analyses were performed for CRAb in each group with their respective exposures.

Statistical Analysis
Statistical analyses among DoD and VA populations were performed by using a non-parametric,
chi-square test to trend infection cases over time. Incidence rates and incidence rate ratios
were calculated from summary data. Significance level at P <0.05 was set for these analyses.
Analyses for this study were performed in Stata 14.2 (StataCorp, College Station, TX)
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Chapter 4 – Results
Study population
The study population for this study involved both personnel from the Department of Defense and
the Veterans Health Administration. In VHA, Veterans are classified by the era of conflict in
which they served under; some veterans can be classified under multiple eras, such as WWII,
Korea and Vietnam. Serving under a particular era does not necessarily mean that a veteran
served in a combat zone; combat zone designations are indicated by the Department of Defense
and Congress. To be considered as having served in a combat deployment, a military member
will be temporarily assigned to serve a tour of duty in one of these locations for a designated
amount of time. This is what is meant by a combat deployment to a battlefield theater.
In VHA, these conflict eras span from World War II era until the present day which is considered
the Gulf War era. The Gulf War era is subdivided by those Veterans that served in the Persian
Gulf War (1990-1991) as well as to the present time which includes Operation Enduring
Freedom and Operation Iraqi Freedom as geographically indicated in Figure 1. As indicated in
Figure 5
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Figure 5. Study population of DoD and VHA

Descriptive data
The distribution of troop levels in both combat theaters over time in Figure 6 show that most of
the commitment of resources were spent in support of Operation Iraqi Freedom.
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Military Personnel in Iraq and Afghanistan FY2003-2012
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Afghanistan
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Figure 6. Number of military personnel in Iraq and Afghanistan from FY2002-2012*
*Data from Congressional Research Service, DoD – Joint Chiefs of Staff, “Boots on the
Ground Reports” [2]
Total enrollments in VA services shown in Figure 6 indicate that during the years that demand
for resources in the form of personnel during the OEF/OIF conflicts were ongoing, there is an
apparent drop in the number of veterans enrolling in VA health services. However, after the
troop surge of 2007, the number of enrollments in VA healthcare services increased substantially
into 2010.
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Total VA Patient Enrollments by Year
600,000

500,000

400,000

300,000

200,000

100,000

0
2003

2004

2005

2006

2007

2008

2009

2010

Figure 7. Total enrollments in VHA from CY2003-2010 across all eras.

Among the most active enrollments were the OEF/OIF veterans enrolling in VA services from
CY 2003-2010 as seen in Figure 7.

OEF/OIF Era Veterans Enrollments by Year
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Figure 8. Enrollments in VHA among OEF/OIF Veterans CY2003-2012

Among OEF/OIF era veterans considered for this study, the proportion of those with a combat
deployment are lower comparatively than those without a combat deployment to an OEF or OIF
battlefield.

OEF/OIF Combat Status at Seperation Date
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Figure 9. Combat status of OEF/OIF Era Veterans by combat deployment status

Outcome data
Incident cases of CS A. baumannii and CRAB infections among DoD military personnel during
the OEF/OIF conflicts indicate that both outcomes were increasing, peaked in 2010 began to fall
by 2011 and fell dramatically as major combat operations diminished in 2012 when most troops
were pulled out from Iraq and mission tempo in Afghanistan had been significantly scaled back.
At which point, cases of both CRAb and A. baumannii are negligible.
Among DoD personnel who sustained a battle injury while in Operation Enduring Freedom
(OEF) and/or Operation Iraqi Freedom (OIF), had 8.2 times the rate of having a CRAb infection
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compared to those without a battle injury during the study period (2008-2012) with an incidence
rate of nearly 10 infections per 1,000 persons compared to those without a battle injury.

Incidence Density/Person Year

DoD OEF/OIF Acinetobacter baumannii & CRAB Incident Cases
120
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40
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Linear (CRAb)

Figure 10. Incident infection cases of A. baumannii and CRAb infections among DoD
personnel from Iraq and Afghanistan battlefields CY 2008-2015

Incident cases of A. baumannii and CRAb infections across VA involving all eras. Figure 10
shows a wide proportion margin between CS A. baumannii cases and CRAb cases.
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Figure 11. Incident infection cases of A. baumannii and CRAB infections among VA
patient across all conflict eras CY2003-2012

Although not as dramatic, in VHA, the observation among OEF/OIF era Veterans was that this
group had 1.7 times the rate of having a CRAb infection as compared to the general VHA
population during the study period (2003-2012) as compared to the general VHA population.
While initially hypothesized to demonstrate a significant relationship between those in the VHA
population who were OEF/OIF Veterans and had a combat deployment to either battlefield
theater and develop CRAb infection or have an incident presentation upon enrollment to VHA,
this group demonstrated a marginal statistical relationship.
In VHA, incident cases of A. baumannii and CRAB among OEF/OIF veterans follows a similar
pattern to DoD group where the margin between the proportion of both outcomes is narrow as
seen in Figure 12.
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Figure 12. Incident infection cases of A. baumannii and CRAB infections among OEF/OIF
Era Veterans only, enrolled in VA health services CY2003-2012
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Table 4. Incidence Rates of CRAb and Acinetobacter baumannii (Ab) infections among
DoD Personnel and VHA Patients Compared to No Exposure
Group

Outcome

Exposure

Observation
Period

Incidence
Rate /1,000
persons
9.831

Incidence
Rate
Ratio
8.2

95%
p-value
Confidence
Interval
DoD
CRAb
Battle Injury 2008-2012
[6.938633,
< .0001
9.643166]
DoD
Ab
Battle Injury 2008-2012
13.108
6.63
[5.790739,
< .0001
7.590315]
DoD
CRAb
Battle Injury 2008-2011* 11.482
8.26
[7.008497,
< .0001
9.740262]
DoD
Ab
Battle Injury 2008-2011* 14.991
6.76
[5.89406,
< .0001
7.752711]
VHA
CRAb
OEF/OIF
2003-2012
0.0728
1.7
[1.441253,
< .0001
Era
1.885047]
VHA
Ab
OEF/OIF
2003-2012
0.1494
0.43
[0.3914165,
< .0001
Era
0.4684096]
OEFOIF CRAb
Combat
2003-2012
0.049
0.92
[0.5642105,
0.7151
1.426329]
OEFOIF Ab
Combat
2003-2012
0.049
0.30
[0.1857809,
< .0001
0.449398]
*By 2012, most DoD personnel had been pulled from Operation Iraqi Freedom (Figures 6 and 10); analysis from
2008 through 2011 was also considered; 2012 omitted.

Results from the linear trend analyses could not be fit in a linear fashion. This formulation sets
the trend as the proportion of CRAb amongst A. baumannii isolates. Due to limited counts, and
other seemingly inconsistent/missing data, CRAb incidence trends were difficult to ascertain.
Among OEF/OIF veterans, so few counts were observed that the statistical package could not
calculate a p-value for the trend. Limitations to this study may have contributed to the gaps in
available data.
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Table 5. Trend Analysis for Proportions of CRAb Infections among DoD Personnel and
VHA Patients
Group

Outcome

Exposure

Observation
Period

Average
Annual
Proportion
al Change
%

Slope /1,000
persons per
year

p-value for
trend

2008-2012

Proportion
al Change
in
Incidence
from 1st
year to Last
year %
**

DoD

CRAb

Battle Injury

61.14

-52.63

0.0178

DoD

CRAb

No Battle
Injury
Battle Injury

2008-2012

**

47.92

0.64

0.9754

DoD

CRAb

2008-2011*

-27.8

76.43

-20.34

0.3736

DoD

CRAb

No Battle
Injury
OEF/OIF
Era
Not
OEF/OIF
Era
Combat
Deployment

2008-2011*

-39.8

59.9

45.59

0.0411

VHA

CRAb

2003-2012

-85.5

50.68

-2.69

0.7352

VHA

CRAb

2003-2012

-84.2

12.55

12.02

< .0001

OEFOIF

CRAb

2003-2012

**

74.00

20.28

**

OEFOIF

CRAb

No Combat
Deployment

2003-2021

-52.5

34.35

-6.64

0.3790

*By 2012, most DoD personnel had been pulled from Operation Iraqi Freedom (Figures 6 and 10); analysis from
2008 through 2011 was also considered; 2012 omitted. ** Insufficient data to perform calculation or statistical test.

Other Analyses Considered
Utilization of healthcare is important when determining risk in a hospital population. Among
OEF/OIF veterans, the likelihood of this group to utilize VHA healthcare services increased as
the percentage of a disability for a service-connected injury increased as indicated in Figure 13
within Appendix A . In other words, those with the most injuries are seeking VHA services.
This is represented in. Service-connected disabled Veteran’s utilization of healthcare services
and benefits increased from 59% in 2007 to 70% by 2016. Over 93% of service-connected
disabled Veterans were enrolled in VHA in 2016 as indicated in Figure 14 within Appendix A.
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Chapter 5 – Discussion
Summary
While there were many MDROs to consider amongst returning OEF/OIF veterans, A. baumannii
was selected for this study because of its ability to specifically impact healthcare settings and the
speed to which it develops resistance [15, 24, 29, 37]. A. baumannii has impacted combat
veterans in a variety of injuries sustained during the OEF/OIF conflicts as lifesaving techniques
and advances in medical evacuation availability have made survival on these battlefields much
more likely [7, 11]. It was hypothesized that this group of returning combat veterans might be
reservoirs for A. baumannii and CRAb infections that could be migrated into hospitals and
medical centers within the Veterans Health Administration and increase infection incidence as a
result.

Key results
We were pleased to see that our findings confirmed higher incidence of CRAb among military
personnel with battle injuries than those without battle injuries. Among DoD personnel who
sustained a battle injury while in Operation Enduring Freedom (OEF) and/or Operation Iraqi
Freedom (OIF), had 8.1 times the rate of having a CRAb infection compared to those without a
battle injury during the study period (2008-2012). In VHA, the observation among OEF/OIF era
Veterans was that this group had 1.7 times the rate of having a CRAb infection as compared to
the general VHA population during the study period (2003-2012). Among OEF/OIF era veterans
in VHA, incidence rates of CRAb among those with and without a previous combat deployment,
there was no statistically significant relationship. We remained puzzled as to the low incidence
of CRAb in VHA and explored these findings further.
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Care of the evacuated casualties has also been improved from previous conflicts to the point
where many soft tissue wounds sustained during combat were no longer infected or even
colonized once arriving at a Level V tertiary medical center (National Naval Medical Center) in
the U.S. upon departure from Level IV care at LRMC and others. Although not a definitive
study, it represents a snapshot of the complexity of wound management from combat areas [38].
This may have contributed to the lack of a statistical support between incidence of CRAb among
OEF/OIF era veterans in VHA that had a combat deployment (exposed) to the OEF/OIF theaters
and those that did not (not exposed).

Other explanations of low incidence of A. baumannii and CRAb cases in VHA could be that by
March 2007, the VHA was able to launch a successful comprehensive initiative aimed at
preventing methicillin-resistant Staphylococcus aureus (MRSA) across the network of 153
medical centers and hospitals [39]. This was a very robust initiative in that it involved admission
screenings for MRSA colonization via nasal swab and required contact precautions (gown and
gloves) for any contact with the patient and their surroundings as well as extensive handwashing
[40]. This program was able to reduce Staphylococcus aureus infections by 43% and MRSA
infections by 55% [39]. While strategically aimed at the prevention of MRSA among VHA
patients, the successful impact this program had on the reduction of incident cases of MRSA may
have carried over into reducing incidence rates of other MDROs such as CRAb. Another study
examining hospital-onset Gram-negative rod (GNR) bacteremia in VHA also noticed that the
success of the MRSA prevention program had a horizontal effect on their initial research target
surrounding the impact of GNRs (E. coli, Klebsiella spp., Pseudomonas aeruginosa) in
bacteremia within VHA [41]. They also discovered because of the MRSA Prevention initiative
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that there was a sustained reduction in hospital-acquired GNR bacteremia incidence rates by 42% from January 2003 until December 2013. Similar observations of lower than normal counts
were made among GNR subgroup analyses of each bacterial species and susceptibility profiles
[41] Another recently published study within VHA examining extensively drug-resistant (XDR)
Acinetobacter baumannii, observed a similar effect among this virulent phenotype [42]. It is not
uncommon for successful infection prevention programs to have these types of effects. In the
civilian non-VHA population, healthcare associated infections among CRAb had decreased from
58% in 2011 [43] to only 39% from 2015 – 2017 [44].
However, this study was able to identify higher incidence rates of CRAb among OEF/OIF era
veterans as compared to the general VA population as seen in Figures 11 and 12, respectively.
While this study found that incidence rate ratio of CRAb in VHA at 1.7 among those OEF/OIF
era veterans compared to the general population at VHA, the study was not able to make a
significant connection among OEF/OIF era with a combat deployment and those without.

Strengths and Limitations
This study underscores the interconnected relationship between the Department of Defense (the
feeding organization) and the Department of Veterans Affairs (the receiving organization) and
why a strong partnership should exist between these two departments of the US Government.
The OEF/OIF conflicts, although the most recent, are not the last that the United States Armed
Forces will be involved in as conditions and threats around the world are in constant flux. Future
conflicts and wars may unearth other emerging pathogens that could threaten our ability to
manage them effectively. Those risks then have the potential to be vertically transferred from
the DoD population to the VHA population. Thus, knowing exactly what they are and what they
are capable of will equip professionals with the tools they will need to be sentries to protect our
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nation’s wounded warriors and prevent unnecessary collateral damage among a vulnerable
population at VHA .
Limitations of this study included the incompleteness of data within the DAVINCI data source.
DAVINCI only captured data from 2008 forward, so earlier analysis of the OEF/OIF conflicts
within the DoD group was not possible. Although not a strong signal in VHA, a closer look at
the OEF/OIF conflicts in their earlier stages would indicate the potential of A. baumannii without
a diluted effect by the time these individuals reach VHA facilities. Furthermore, the DAVINCI
data source captured mostly VA-enrolled patients and we were therefore unable to assess those
that did not enroll in VA services. As a result, we were unable to perform an appropriate
comparative analysis between DoD and VA populations during the early years of the OEF/OIF
conflicts (2003-2007). Future studies on this topic should consider using the Joint Theater
Trauma Registry (JTTR), which is the definitive source for battlefield injuries sustained during
combat operations for the United States Armed Forces.
Further limitations are the inconsistent laboratory practices for identification of MDROS within
VHA. These inconsistencies among the carbapenem-producing organisms (CPOs) produce
ambiguity in the surveillance results and subsequent infection control procedures . Although the
VHA is a national organization with directives aimed nationwide, many local practices are what
prevail [8].

Interpretation
This study underscores the need for cooperation in many areas between the DoD and VA due to
the upstream-downstream relationship of these two departments. The first area where
cooperation is needed is records management. At the present time, records for military members
are maintained within DoD and not well-shared with VA. In April 2020, the joint Health
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Information Exchange (HIE) launched, which is a major step forward in the exchange of medical
data, but still a significant distance from ideal. This can make medical histories challenging for
VA physicians and other professionals to get an accurate representation of the challenges a
particular patient may be experiencing if left to incomplete medical records or patient reporting
only. However, there is a push to streamline one single record that will follow a military recruit
from basic training to separation from military service and into VHA as part of the Federal
Electronic Health Record Modernization Program, which the findings of this report support.
The second major area of cooperation is the research and development efforts the DoD has
engaged on with regard to the diagnostics and epidemiology that have been done on the lab
results of those afflicted with pathogenic microorganisms while in military service, particularly
the molecular infrastructure that can definitively identify highly problematic pathogens, such as
the ESKAPE cluster of pathogens that have such a major impacts on healthcare [7, 21, 34].

Many medical centers throughout the VHA rely upon only culture-based lab data for
identification, diagnosis and later treatment of infections impacting veteran patients [8]. While
culture data cannot be replaced entirely, rapid nucleic acid identification is the direction clinical
labs by and large have adopted in providing accurate diagnostics in healthcare settings.
Pneumonia for example is one of the leading causes of death in the world. Lower respiratory
infections are the 4th greatest cause of mortality in the world; responsible for 2.6 million deaths
globally in 2019 [45]. In the United States alone in 2017, 1.3 million instances occurred where
pneumonia was listed as the primary diagnosis [46]. Furthermore, this disease has an economic
impact of ~$10 billion in the United States [47]. Pneumonia is a communicable disease affecting
all age groups and is characterized by infections of viral and/or bacterial and/or fungal
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pathogens. This makes the identification of a pneumonia-causing pathogen or even multiple
pathogens, challenging for providers and further complicates treatment planning for favorable
clinical outcomes. While in-vitro culture and Gram staining have been standard practice of
microbial identification in clinical microbiology since the days of Pasteur in the late 19th century,
these methods have their limitations. Cultures, for example, take time 24-48 hours for most
aerobic organisms and even longer for those anaerobic or more fastidious in nature [48].
Multiplex real-time quantitative polymerase chain reaction (qPCR) is a molecular diagnostic
assay that can detect organisms in real-time using nucleic acids which culture may not be able to
successfully recover. A major advantage of the syndromic testing of the pneumonia panel is the
ability to detect polymicrobial infections in which viral-viral infections may be detected or
bacteria-bacteria, or even if viral-bacterial infections are occurring [49]. One such qPCR
manufacturer, BioFire® FilmArray® Pneumonia (PN) Panel, will produce a rapid molecular
analysis report in about 1 hour across 33 different targets from sputum, endotracheal aspirate and
bronchoalveolar lavage (BAL) clinical samples. These targets involve 8 common respiratory
viruses, 15 common pneumonia-causing bacteria, 3 atypical bacteria. An added value of the PN
panel is its ability to also detect select antimicrobial resistance genes: Methicillin resistance (x3),
carbapenemases (x6) and extended spectrum beta-lactamases [49]. This rapid information can
provide the treating physician with real-time information about the pathogen/s afflicting their
patients so they can make the most informed decision about an appropriate treatment plan to
produce the best possible clinical outcome and protect the integrity of the antibiotic stewardship
plan at a local or national level by not propagating antibiotic resistance by improper broadspectrum empiric therapies [50].
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Another molecular technique that will provide the best and most complete information about a
microbial pathogen for VA epidemiologists, clinical laboratory scientists, pharmacists and
treating physicians is a technology called whole-genome sequencing (WGS) [9]. WGS is a
molecular technique that maps out an organism’s entire genome in a single run and is the future
of medicine at the personal level. What this allows medical scientists to do is see the full
potential of the organism at a molecular level and understand the lineage of that organism
through phylogenetic mapping by comparing the regions of the genome by means of a collection
of single nucleotide polymorphisms (SNPs). In one study, A. baumannii isolates at the clonal
level were able to be identified at a threshold of 2,500 core SNPs, while CRAb outbreak strains
were identified at a threshold of 2.5 core SNPs [9]. WGS has a great deal of application towards
ESKAPE pathogens and other MDROs in detecting strain types and investigations into outbreaks
[9, 21, 50]. A. baumannii strain recognition, has medically important consequences as each
clonal lineage has different impacts to healthcare settings and their populations [9, 18, 23].

Many of the lab techniques in practice today in VHA only identify some phenotypical expression
in resistance to any given antimicrobial and only provide a limited picture of what MDROs are
capable of genotypically. This gap among identification of MDROs exists in the civilian
population but has also been underscored in VHA [8, 42]. Thus, there is a great missed
opportunity at VHA to understand the pathogenic potential and the epidemiological patterns
these organisms follow and may suggest that CRAb and other MDROs are underreported and
could be another reason for such low CRAb incidence in VHA [9, 42]. We suggest the VHA
either develop an in-house central reference laboratory or regional laboratories for highthroughput WGS or utilize a third-party reference laboratory to acquire such information. This
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will help to better identify outbreak strains that are problematic for those in ICUs. Costs for
WGS have consistently been a major barrier for integration in clinical laboratories for many
organizations, however WGS is projected to get cheaper and cheaper as time goes on and
therefore, VHA should be strategically planning and implementing policies and directives for the
future of hospital epidemiology, infection prevention, infection control and antibiotic
stewardship [9, 42].

Conclusion
Further studies using molecular data are required across large hospital systems or networks to
determine if related strains are circulated and transmitted patient-to-patient or patient-to-staff
member within the network to determine if the results of this study are generalizable. Awareness
of the epidemiological impact of newly VA-enrollees from DoD as reservoirs should compel
VHA leadership to modernize the electronic medical record, modernize current pathogen
identification and surveillance systems, reconsider local and national drug formularies based off
what organisms are present or threatening the population, and adjust antibiotic stewardship plans
accordingly. While this study did not assess treatment outcomes for CRAb, it echoes the
literature in calling for the development of new antimicrobials against MDROs [1, 51] in order
to prevent the troubling prophecies of a post-antibiotic era in which the drugs we as a society
have relied upon for years will be less and less effective and there are no other treatment options
remaining.
MDROs such as A. baumannii, are making decisions for their survival at the molecular level as
to how they adapt to thrive in their environments, whether that is in nature as a wildtype
organism or as an opportunistic nosocomial pathogen in a healthcare facility. Our understanding
of MDROs, research and development of new drugs/treatments, epidemiologic surveillance,
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infection prevention practices and currently available treatments of MDRO infections also need
to be at the molecular level if we as a medical community want to make a significant impact to
the health and wellness of the populations we serve.
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Appendix A: VHA Health Care Utilization

Figure 13 - Service-connected disabled Veteran’s utilization of healthcare services and
benefits increased from 59% in 2007 to 70% by 2016. Over 93% of service-connected
disabled Veterans were enrolled in VHA in 2016
Source: U.S. Veterans Eligibility Trends and Statistics, 2016 [52]
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Figure 14 - The likelihood of Veterans with a service-connected disability pursuing VHA
health benefits and services increase as the Veteran’s disability rating increases from 0100% disabling.
Source: U.S. Veterans Eligibility Trends and Statistics, 2016 [52]
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